The characterization of methoxetamine, a ketamine analog, and how its action on the serotonin system sets it apart.
Psychedelic-assisted psychotherapy leads the way in 2020’s top psychedelic papers.
The monoamine hypothesis of depression leaves many patients without effective help. It’s time for a paradigm shift, and psychedelics may be leading the way.
Feasibility, safety, and potential efficacy of psilocybin-assisted group therapy was demonstrated in treating demoralization in this marginalized population.
New research shows that ketamine reduces self-dislike, loosening the rigid prejudice toward oneself that can constitute depression.
Experiential avoidance is one transdiagnostic process that may be implicated in the therapeutic benefits of psychedelics.
While ketamine produces a whole symphony of effects in the brain, surprisingly, a localized neural oscillation in a lesser-known area of the brain is enough to cause feelings of dissociation.
Both have long-lasting positive effects on mood, social skills and neuroplasticity. Combining them may potentiate and prolong mutual therapeutic effects.
Research suggests that BDNF can help rewire and overwrite stubborn neural pathways by creating new connections that facilitate more flexible and adaptive thoughts and behaviours. Psychedelics appear to tap into this mechanism.
THC binding to 5-HT2A may activate signaling pathways that cause negative effects on cognition and memory.